Ocean Biomedical, Inc. financial data

Symbol
OCEA, OCEAW on OTC
Location
515 Madison Ave Suite 8078, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - May 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.76 % -36.1%
Debt-to-equity -101 % +2.3%
Return On Equity 32.4 % -16.3%
Return On Assets -2.25K % -123%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 166M shares +379%
Common Stock, Shares, Outstanding 166M shares +377%
Entity Public Float 5.47M USD +547391452%
Weighted Average Number of Shares Outstanding, Basic 91M shares +233%
Weighted Average Number of Shares Outstanding, Diluted 91M shares +233%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 18K USD -30.8%
General and Administrative Expense 4.14M USD -18.4%
Operating Income (Loss) -4.16M USD +23.3%
Nonoperating Income (Expense) -26.6M USD -10.9%
Net Income (Loss) Attributable to Parent -30.7M USD -4.58%
Earnings Per Share, Basic -1 USD/shares +6.19%
Earnings Per Share, Diluted -1 USD/shares +6.19%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 1.49M USD -17.1%
Assets 1.58M USD -46.3%
Accounts Payable, Current 16.4M USD -2.92%
Accrued Liabilities, Current 946K USD +113%
Liabilities, Current 26.6M USD -11.8%
Liabilities 94M USD +19.4%
Retained Earnings (Accumulated Deficit) -214M USD -16.8%
Stockholders' Equity Attributable to Parent -92.4M USD -21.9%
Liabilities and Equity 1.58M USD -46.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -356K USD +26.6%
Net Cash Provided by (Used in) Financing Activities 909K USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 166M shares +377%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 553K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 800K USD
Deferred Tax Assets, Valuation Allowance 22.6M USD +8.83%
Deferred Tax Assets, Gross 22.6M USD +8.83%
Deferred Tax Assets, Operating Loss Carryforwards 7.64M USD +28.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares +700%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 121M USD +13.1%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 745K USD 0%
Interest Expense 50K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%